Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04825990 |
| Title | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT) |
| Acronym | POINT |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Gruppo Oncologico del Nord-Ovest |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | ITA |